Please Wait.....
Report
Global HIV Drugs Market Report and Forecast 2023-2031
Market Report I 2023-05-08 I 160 Pages I EMR Inc.
Global HIV Drugs Market Report and Forecast 2023-2031
Global HIV Drugs Market Outlook
The global HIV drugs market value was USD 32.1 billion in 2022, driven by the increasing prevalence of HIV across the globe. The market size is anticipated to grow at a CAGR of 4.5% during the forecast period of 2023-2031 to achieve a value of USD 47.8 billion by 2031.
HIV Drugs: Introduction
Human Immunodeficiency Virus (HIV) continues to be a significant global public health issue, affecting millions of people worldwide. HIV drugs, specifically antiretroviral therapy (ART), have played a crucial role in managing the disease and improving the quality of life for those living with HIV. ART involves the use of a combination of drugs that work together to suppress the virus, prevent its progression to Acquired Immune Deficiency Syndrome (AIDS), and reduce the risk of transmission.
HIV Drugs Market Scenario
In recent years, the global HIV drugs market has witnessed considerable growth, driven by factors such as the increasing prevalence of HIV, advancements in antiretroviral therapy, the development of novel treatment regimens, and a growing focus on expanding access to treatment in low- and middle-income countries. The market is also fuelled by the rising demand for innovative therapies that offer improved efficacy, fewer side effects, and better patient adherence compared to traditional treatments.
The adoption of HIV drugs has been increasing steadily as the prevalence of HIV remains high, and advancements in antiretroviral therapy led to the development of more effective and tolerable treatments. The increasing focus on expanding access to treatment in low- and middle-income countries has further fuelled the growth of the market, as these regions account for a significant proportion of the global HIV burden.
HIV Drugs Market Segmentations
Market Breakup by Drug Class
- Nucleoside Reverse Transcriptase Inhibitors
- Multi-Class Combination Drugs
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors - CCR5 Co-Receptor Antagonist
- Fusion Inhibitors
- Others
Market Breakup by Route of Administration
- Oral
- Tablets
- Capsules
- Parenteral
- Intravascular
- intramuscular
- Others
Market Breakup by Drug Type
- Branded
- Generics
Market Breakup by End User
- Hospitals
- Clinics
- Specialty Centers
- Research Institutes
- Others
Market Breakup by Distribution Channels
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- North America
- United States of America
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Others
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
- Latin America
- Brazil
- Argentina
- Mexico
- Others
- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Trends in the HIV Drugs Market
- New antiretroviral drugs and regimens: The development of novel antiretroviral drugs and treatment regimens has improved treatment outcomes and reduced side effects, leading to better patient adherence and overall quality of life.
- Long-acting injectable therapies: The emergence of long-acting injectable HIV therapies has the potential to revolutionize treatment by reducing the burden of daily oral medication and improving treatment adherence.
- Expanding access to treatment: Global efforts to increase access to antiretroviral therapy in low- and middle-income countries have contributed to the growth of the HIV drugs market.
- Drug resistance and treatment optimization: Ongoing research focuses on addressing the issue of drug resistance, as well as optimizing treatment regimens to minimize side effects and maximize efficacy.
- Prevention strategies: The market is also witnessing growth in the demand for pre-exposure prophylaxis (PrEP) drugs, which are used to prevent HIV infection in high-risk individuals.
HIV Drugs Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- AstraZeneca
- GSK plc
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Mylan N.V.
- Sanofi
- Bayer AG
- ViiV Healthcare group of companies
- Genentech, Inc
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 HIV/AIDS Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 HIV/AIDS Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America HIV Epidemiology (2016-2031)
5.3 Europe HIV Epidemiology (2016-2031)
5.4 Asia-Pacific HIV Epidemiology (2016-2031)
5.5 Latin America HIV Epidemiology (2016-2031)
5.6 Middle East & Africa HIV Epidemiology (2016-2031)
6 Global HIV Drugs Market Overview
6.1 Global HIV Drugs Market Historical Value (2016-2022)
6.2 Global HIV Drugs Market Forecast Value (2023-2031)
7 Global HIV Drugs Market Landscape
7.1 Global HIV Drugs Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global HIV Drugs Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by End User
7.2.3 Analysis by Distribution Channel
8 Cost of Treatment
9 Global HIV Drugs Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter's Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Global HIV Drugs Market Segmentation
10.1 Global HIV Drugs Market by Drug Class
10.1.1 Market Overview
10.1.2 Nucleoside Reverse Transcriptase Inhibitors
10.1.3 Multi-Class Combination Drugs
10.1.4 Protease Inhibitors
10.1.5 HIV Integrase Strand Transfer Inhibitors
10.1.6 Non-Nucleoside Reverse Transcriptase Inhibitors
10.1.7 Entry Inhibitors - CCR5 Co-Receptor Antagonist
10.1.8 Fusion Inhibitors
10.1.9 Others
10.2 Global HIV Drugs Market by Route of Administration
10.2.1 Market Overview
10.2.2 Oral
10.2.2.1 Tablets
10.2.2.2 Capsules
10.2.3 Parenteral
10.2.3.1 Intravascular
10.2.3.2 intramuscular
10.2.3.3 Others
10.3 Global HIV Drugs Market by Drug Type
10.3.1 Market Overview
10.3.2 Branded
10.3.3 Generics
10.4 Global HIV Drugs Market by End User
10.4.1 Market Overview
10.4.2 Hospitals
10.4.3 Clinics
10.4.4 Specialty Centers
10.4.5 Research Institutes
10.4.6 Others
10.5 Global HIV Drugs Market by Distribution Channels
10.5.1 Market Overview
10.5.2 Hospitals Pharmacies
10.5.3 Retail Pharmacies
10.5.4 Online Pharmacies
10.5.5 Others
10.6 Global HIV Drugs Market by Region
10.6.1 Market Overview
10.6.2 North America
10.6.3 Europe
10.6.4 Asia Pacific
10.6.5 Latin America
10.6.6 Middle East and Africa
11 North America HIV Drugs Market
11.1 Market Share by Country
11.2 United States of America
11.3 Canada
12 Europe HIV Drugs Market
12.1 Market Share by Country
12.2 United Kingdom
12.3 Germany
12.4 France
12.5 Italy
12.6 Others
13 Asia Pacific HIV Drugs Market
13.1 Market Share by Country
13.2 China
13.3 Japan
13.4 India
13.5 ASEAN
13.6 Australia
13.7 Others
14 Latin America HIV Drugs Market
14.1 Market Share by Country
14.2 Brazil
14.3 Argentina
14.4 Mexico
14.5 Others
15 Middle East and Africa HIV Drugs Market
15.1 Market Share by Country
15.2 Saudi Arabia
15.3 United Arab Emirates
15.4 Nigeria
15.5 South Africa
15.6 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by Year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Regulatory Framework
21.1 Regulatory Overview
21.1.1 US FDA
21.1.2 EU EMA
21.1.3 INDIA CDSCO
21.1.4 JAPAN PMDA
21.1.5 Others
22 Supplier Landscape
22.1 F. Hoffmann-La Roche Ltd.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Bristol-Myers Squibb Company
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 AstraZeneca
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 GSK plc
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Merck & Co., Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Novartis AG
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Pfizer Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Sun Pharmaceutical Industries Ltd
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Mylan N.V.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Sanofi
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Bayer AG
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 ViiV Healthcare group of companies
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Genentech, Inc
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
23 Global HIV Drugs Market-Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security